These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 33962838)

  • 21. Surveillance to Track Progress Toward Polio Eradication - Worldwide, 2020-2021.
    Wilkinson AL; Diop OM; Jorba J; Gardner T; Snider CJ; Ahmed J
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(15):538-544. PubMed ID: 35421079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Advances in researches of serotype 2 novel oral polio vaccine].
    Chen SY; Li Y; Yang JS; Yin XX
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Mar; 55(3):413-417. PubMed ID: 33730837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Risk Anal; 2021 Feb; 41(2):248-265. PubMed ID: 31960533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress toward poliomyelitis eradication --- Nigeria, January 2010-June 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Aug; 60(31):1053-7. PubMed ID: 21832977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
    Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
    Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication.
    Kew O; Pallansch M
    Annu Rev Virol; 2018 Sep; 5(1):427-451. PubMed ID: 30001183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
    Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs).
    Thompson KM; Badizadegan K
    Expert Rev Vaccines; 2024; 23(1):597-613. PubMed ID: 38813792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.
    Bigouette JP; Henderson E; Traoré MA; Wassilak SGF; Jorba J; Mahoney F; Bolu O; Diop OM; Burns CC
    MMWR Morb Mortal Wkly Rep; 2023 Apr; 72(14):366-371. PubMed ID: 37022974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling and Managing Poliovirus Risks: We are Where we are….
    Thompson KM
    Risk Anal; 2021 Feb; 41(2):223-228. PubMed ID: 33590520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polio Eradication and Endgame Plan - Victory within Grasp.
    Patel M; Menning L; Bhatnagar P
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S28-S32. PubMed ID: 27771636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress toward poliomyelitis eradication - Nigeria, January 2011-September 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Nov; 61(44):899-904. PubMed ID: 23134973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress Toward Polio Eradication - Worldwide, January 2017-March 2019.
    Greene SA; Ahmed J; Datta SD; Burns CC; Quddus A; Vertefeuille JF; Wassilak SGF
    MMWR Morb Mortal Wkly Rep; 2019 May; 68(20):458-462. PubMed ID: 31120868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
    Duintjer Tebbens RJ; Thompson KM
    Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poliomyelitis amidst the COVID-19 pandemic in Africa: Efforts, challenges and recommendations.
    Uwishema O; Elebesunu EE; Bouaddi O; Kapoor A; Akhtar S; Effiong FB; Chaudhary A; Onyeaka H
    Clin Epidemiol Glob Health; 2022; 16():101073. PubMed ID: 35664665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.